As the FTSE 100 and FTSE 250 indices reflect the impact of global economic challenges, notably from China’s sluggish recovery, investors are navigating a complex landscape in the UK market. In such conditions, identifying stocks that may be undervalued can present opportunities for those looking to capitalize on potential market inefficiencies.
|
Name |
Current Price |
Fair Value (Est) |
Discount (Est) |
|
XP Power (LSE:XPP) |
£13.40 |
£23.68 |
43.4% |
|
Taylor Wimpey (LSE:TW.) |
£0.8822 |
£1.75 |
49.7% |
|
Pinewood Technologies Group (LSE:PINE) |
£2.19 |
£4.12 |
46.8% |
|
Pan African Resources (LSE:PAF) |
£1.57 |
£3.11 |
49.5% |
|
James Fisher and Sons (LSE:FSJ) |
£4.99 |
£9.22 |
45.9% |
|
Fevertree Drinks (AIM:FEVR) |
£8.225 |
£15.73 |
47.7% |
|
Eurocell (LSE:ECEL) |
£1.16 |
£2.11 |
44.9% |
|
Entain (LSE:ENT) |
£5.842 |
£10.42 |
44% |
|
ACG Metals (LSE:ACG) |
£14.80 |
£26.72 |
44.6% |
|
Accsys Technologies (AIM:AXS) |
£0.606 |
£1.16 |
47.6% |
Underneath we present a selection of stocks filtered out by our screen.
Overview: Fevertree Drinks PLC, along with its subsidiaries, develops and sells mixer drinks in the UK, US, Europe, and internationally with a market cap of £949.12 million.
Operations: The company’s revenue segments include £131.90 million from the US and £243.40 million from the rest of the group.
Estimated Discount To Fair Value: 47.7%
Fevertree Drinks appears undervalued based on cash flow analysis, trading at £8.23, which is 47.7% below its estimated fair value of £15.73. Despite recent declines in sales and net income for 2025, the company is projected to experience significant earnings growth of 20.9% annually over the next three years, outpacing the UK market average. Revenue growth is also expected to surpass the market at 10.2% per year, supporting its potential as a value investment opportunity in cash flow terms.
Overview: CVS Group plc operates veterinary services, an online pharmacy, and retail businesses in the United Kingdom and Australia, with a market cap of £833.46 million.
Operations: The company’s revenue segments include £632.70 million from veterinary practices, £33 million from laboratories, and £47.90 million from its online retail business.
Estimated Discount To Fair Value: 30.8%
CVS Group, trading at £11.88, is considered undervalued on a cash flow basis with an estimated future value of £17.17, representing a discount exceeding 20%. Despite recent declines in net income for the half year ending December 2025, CVS is expected to achieve significant annual earnings growth of 21%, outpacing the UK market average. However, it carries a high debt level and its revenue growth forecast of 4.6% per year slightly exceeds market expectations.
